Comprehensive review of fetal adenocarcinoma of the lung

Luisa María Ricaurte,1 Oscar Arrieta,2 Zyanya Lucia Zatarain-Barrón,2 Andrés F Cardona1,3 1Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia; 2Thoracic Oncology Unit, National Cancer Institute (INCan), Méxi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ricaurte LM, Arrieta O, Zatarain-Barrón ZL, Cardona AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	lung cancer fetal adenocarcinoma outcomes chemotherapy radiotherapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b1a5568e4fe842a1a2d5656d0acb2fad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1a5568e4fe842a1a2d5656d0acb2fad
record_format	dspace
spelling	oai:doaj.org-article:b1a5568e4fe842a1a2d5656d0acb2fad2021-12-02T08:47:41ZComprehensive review of fetal adenocarcinoma of the lung1179-2728https://doaj.org/article/b1a5568e4fe842a1a2d5656d0acb2fad2018-08-01T00:00:00Zhttps://www.dovepress.com/comprehensive-review-of-fetal-adenocarcinoma-of-the-lung-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Luisa María Ricaurte,1 Oscar Arrieta,2 Zyanya Lucia Zatarain-Barrón,2 Andrés F Cardona1,3 1Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia; 2Thoracic Oncology Unit, National Cancer Institute (INCan), México City, México; 3Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia Abstract: Fetal adenocarcinoma of the lung (FLAC) is a rare tumor. It accounts for ~0.1%–0.5% of all pulmonary neoplasms. Due to its rarity, much of the world literature regarding FLAC comes from case reports and case series. FLAC is an adenocarcinoma resembling developing fetal lung in its pseudoglandular stage (8–16 weeks of gestation). It is distinguishable from pulmonary blastoma (PB) because it lacks the mesenchymal component which is a hallmark finding in PB. Due to differences in histopathology and clinical course, FLAC has been further categorized into low-grade (L-FLAC) and high-grade (H-FLAC) forms. L-FLAC displays low nuclear atypia and prominent morule formation and has a pure pattern. H-FLAC typically presents with at least 50% fetal morphology, and is often associated with other conventional types of lung adenocarcinoma. FLAC expresses neuroendocrine markers and thyroid transcription factor 1 in most cases. L-FLAC has an aberrant nuclear/cytoplasmic expression of β-catenin and presents mutations in this gene. H-FLAC overexpresses p53. These tumors have a very low frequency of mutations in KRAS and EGFR; it is thought that they are different from a molecular point of view to conventional lung adenocarcinomas. Approximately 25%–40% of patients are asymptomatic at presentation; most of them are incidental findings on chest radiographs. H-FLAC is more common in elderly male patients, with a heavy smoking history. L-FLAC tends to occur in young females. Patients with L-FLAC are usually diagnosed with stage I–II disease, while patients with H-FLAC usually present with a more advanced-stage disease. Poor prognostic factors for FLAC are thoracic lymphadenopathy, metastases at diagnosis, and tumor recurrence; however, the 10-year survival for FLAC is estimated at 75%. Keywords: lung cancer, fetal adenocarcinoma, outcomes, chemotherapy, radiotherapy, L-FLAC, H-FLAC, p53Ricaurte LMArrieta OZatarain-Barrón ZLCardona AFDove Medical Pressarticlelung cancerfetal adenocarcinomaoutcomeschemotherapyradiotherapy.Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 9, Pp 57-63 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer fetal adenocarcinoma outcomes chemotherapy radiotherapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung cancer fetal adenocarcinoma outcomes chemotherapy radiotherapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ricaurte LM Arrieta O Zatarain-Barrón ZL Cardona AF Comprehensive review of fetal adenocarcinoma of the lung
description	Luisa María Ricaurte,1 Oscar Arrieta,2 Zyanya Lucia Zatarain-Barrón,2 Andrés F Cardona1,3 1Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia; 2Thoracic Oncology Unit, National Cancer Institute (INCan), México City, México; 3Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia Abstract: Fetal adenocarcinoma of the lung (FLAC) is a rare tumor. It accounts for ~0.1%–0.5% of all pulmonary neoplasms. Due to its rarity, much of the world literature regarding FLAC comes from case reports and case series. FLAC is an adenocarcinoma resembling developing fetal lung in its pseudoglandular stage (8–16 weeks of gestation). It is distinguishable from pulmonary blastoma (PB) because it lacks the mesenchymal component which is a hallmark finding in PB. Due to differences in histopathology and clinical course, FLAC has been further categorized into low-grade (L-FLAC) and high-grade (H-FLAC) forms. L-FLAC displays low nuclear atypia and prominent morule formation and has a pure pattern. H-FLAC typically presents with at least 50% fetal morphology, and is often associated with other conventional types of lung adenocarcinoma. FLAC expresses neuroendocrine markers and thyroid transcription factor 1 in most cases. L-FLAC has an aberrant nuclear/cytoplasmic expression of β-catenin and presents mutations in this gene. H-FLAC overexpresses p53. These tumors have a very low frequency of mutations in KRAS and EGFR; it is thought that they are different from a molecular point of view to conventional lung adenocarcinomas. Approximately 25%–40% of patients are asymptomatic at presentation; most of them are incidental findings on chest radiographs. H-FLAC is more common in elderly male patients, with a heavy smoking history. L-FLAC tends to occur in young females. Patients with L-FLAC are usually diagnosed with stage I–II disease, while patients with H-FLAC usually present with a more advanced-stage disease. Poor prognostic factors for FLAC are thoracic lymphadenopathy, metastases at diagnosis, and tumor recurrence; however, the 10-year survival for FLAC is estimated at 75%. Keywords: lung cancer, fetal adenocarcinoma, outcomes, chemotherapy, radiotherapy, L-FLAC, H-FLAC, p53
format	article
author	Ricaurte LM Arrieta O Zatarain-Barrón ZL Cardona AF
author_facet	Ricaurte LM Arrieta O Zatarain-Barrón ZL Cardona AF
author_sort	Ricaurte LM
title	Comprehensive review of fetal adenocarcinoma of the lung
title_short	Comprehensive review of fetal adenocarcinoma of the lung
title_full	Comprehensive review of fetal adenocarcinoma of the lung
title_fullStr	Comprehensive review of fetal adenocarcinoma of the lung
title_full_unstemmed	Comprehensive review of fetal adenocarcinoma of the lung
title_sort	comprehensive review of fetal adenocarcinoma of the lung
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b1a5568e4fe842a1a2d5656d0acb2fad
work_keys_str_mv	AT ricaurtelm comprehensivereviewoffetaladenocarcinomaofthelung AT arrietao comprehensivereviewoffetaladenocarcinomaofthelung AT zatarainbarronzl comprehensivereviewoffetaladenocarcinomaofthelung AT cardonaaf comprehensivereviewoffetaladenocarcinomaofthelung
_version_	1718398384783491072

Comprehensive review of fetal adenocarcinoma of the lung

Ejemplares similares